Coronary Artery Stenosis Clinical Trial
Official title:
A Randomized Crossover Study to Evaluate and Compare the Reproducibility and Tolerability of Direct Wire Pacing for Measuring Fractional Flow Reserve Versus Standard Method in Subjects With FFR Indications
This is a randomized, non-inferiority, crossover investigation comparing the Direct Wire Pacing (DWP) versus standard method to measure Fractional Flow Reserve (FFR) in subjects with FFR indications. All subjects requiring on a clinical basis a pressure wire assessment of coronary artery stenosis(es) will be eligible to take part in the study.
Pressure wire-based Fractional Flow Reserve (FFR) has become the reference standard index of haemodynamic significance to guide revascularisation of intermediate coronary artery lesions. The FFR measurement determines the ratio of the maximum blood flow that can be achieved in a diseased or narrowed coronary artery to the maximum blood flow in a normal coronary artery. This ratio represents the potential decrease in distal coronary flow relative to coronary stenosis. FFR is easily measured during routine coronary angiography using a pressure wire to calculate the ratio of coronary pressure distal to a stenosis or diseased segment to aortic pressure under conditions of maximum myocardial hyperemia. An FFR of 1.0 is widely accepted as normal. An FFR of less than 0.80 is generally considered to be associated with coronary ischemia and widely accepted in favor of revascularization rather than conservative management. The current standard method of measuring FFR is to insert a pressure wire into the coronary artery while the hyperaemic agent, usually adenosine, is delivered by intracoronary bolus or continuous intravenous injection. Administration of adenosine may cause bradycardia and thus cause patient vagal discomfort. Direct Wire Pacing (DWP) can potentially overcome the drawbacks of the standard method when measuring FFR. Indeed, DWP allows to transmit an electrical current from the external pacemaker to the heart thanks to metallic FFR guidewire already used, and thus prevent bradycardia. In addition, there are some absolute contraindications to the use of Adenosine such as 2nd or 3rd degree atrioventricular block, untreated sinus dysfunction or long QT syndrome ...DWP could allow this highly recommended diagnostic tool (1A) to be used in this patient population. The investigators would therefore like to determine if the measurement of FFR by DWP would be non-inferior to the standard method to obtain precise FFR values and maximize patient's comfort. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05133843 -
Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis
|
N/A | |
Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
Completed |
NCT01332591 -
Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy.
|
N/A | |
Completed |
NCT01182428 -
XIENCE V: SPIRIT WOMEN Sub-study
|
Phase 4 | |
Completed |
NCT00739466 -
Biorest Liposomal Alendronate With Stenting sTudy (BLAST)
|
Phase 2 | |
Completed |
NCT01310309 -
EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease
|
Phase 4 | |
Completed |
NCT00531011 -
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
|
Phase 4 | |
Not yet recruiting |
NCT06052670 -
Functional Diagnostic Accuracy of Ultrasonic Flow Ratio in Assessment of Coronary Artery Lesions
|
||
Completed |
NCT05509296 -
Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease
|
N/A | |
Not yet recruiting |
NCT05393882 -
Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
|
||
Recruiting |
NCT06397820 -
Relation Between AI-QCA and Cardiac PET
|
||
Active, not recruiting |
NCT01960504 -
First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)
|
N/A | |
Completed |
NCT01721096 -
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
|
||
Active, not recruiting |
NCT01342822 -
Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization
|
Phase 4 | |
Completed |
NCT01205789 -
EXCEL Clinical Trial (Universal Registry)
|
N/A | |
Recruiting |
NCT05532605 -
Effects of Mindfulness Based Therapy on Illness and Depression in Cardiac Rehab Phase-i
|
N/A | |
Completed |
NCT02066623 -
Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold
|
||
Not yet recruiting |
NCT02946320 -
Optimal Predilatation Technique for BVS Implantation
|
Phase 3 | |
Completed |
NCT01249027 -
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
|
||
Terminated |
NCT01136915 -
Kidney Damage In Patients With Severe Fall In eGFR
|
Phase 4 |